Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 5/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23410381 | 0.98 | USP2 (0.39) | USP2SMN1; SMN2ACACBL3MBTL3L3MBTL1 | |
| SCHEMBL14801521 | 0.91 | ALDH1A1 (0.42) | USP2SMN1; SMN2ACACBNR1H2CYP11B2 | |
| SCHEMBL484569 | 0.90 | ACACB (0.43) | USP2SMN1; SMN2ACACBNR1H2CYP11B2 | |
| SCHEMBL31735245 | 0.89 | ALDH1A1 (0.39) | USP2SMN1; SMN2ACACBNR1H2CYP11B2 | |
| SCHEMBL617801 | 0.89 | CYP11B2 (0.45) | USP2SMN1; SMN2ACACBL3MBTL3L3MBTL1 | |
| SCHEMBL29427773 | 0.89 | CYP11B2 (0.45) | USP2SMN1; SMN2ACACBL3MBTL3L3MBTL1 | |
| SCHEMBL30684021 | 0.89 | CYP11B2 (0.45) | USP2SMN1; SMN2ACACBL3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL994315 | 0.89 | ACACB (0.42) | USP2SMN1; SMN2ACACBNR1H2CYP11B2 | |
| Hydrochloric Acid SCHEMBL993329 | 0.88 | TSHR (0.44) | USP2SMN1; SMN2ACACBL3MBTL3L3MBTL1 | |
| SCHEMBL31486924 | 0.87 | ACACB (0.35) | USP2SMN1; SMN2ACACBNR1H2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114667145-A | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders | 拜尔哈文制药股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| CN-113135921-B | Dihydropyrimidine-spiro derivative and preparation method and application thereof | 山东大学 | 2022-06-17 | — | — | CN | claimed |
| EP-4746965-A1 | BENZIMIDAZOLES AS SIK-ACTIVITY MODULATORS | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| CN-122055156-A | (R) -N-ethyl-5-fluoro-N-isopropyl-2- ((5- (2- (6- ((2-methoxyethyl) (methyl) amino) -2-methyl-hex-3-yl) -2, 6-diazaspiro [3.4] oct-6-yl) -1,2, 4-triazin-6-yl) oxy) benzamide, formulations and dosing regimens for treating cancer | 詹森药业有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260125387-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-07 | — | — | US | disclosed |
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12577257-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4698182-A1 | COMBINATION OF A MENIN-LL1 INHIBITOR, A DNA INTERCALATING AGENT AND A PYRIMIDINE ANALOGUE TO TREAT A HEMATOPOIETIC DISORDER | Janssen Pharmaceutica NV (BE) | 2026-02-25 | — | — | EP | disclosed |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| WO-2013033228-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013019561-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-1987020-B1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI SA (FR) | 2012-10-03 | — | — | EP | disclosed |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-10-22 | — | — | US | disclosed |
| EP-1987020-A1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093364-A1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK2, CHEK1 | USP2 1785/4885SMN1; SMN2 841/4885ACACB 1452/4885 |
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MRGPRX1, MRGPRX4 | USP2 3208/4885SMN1; SMN2 3276/4885ACACB 3834/4885 |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | USP2 4387/4885SMN1; SMN2 2578/4885ACACB 1717/4885 |
| US-12577257-B2 | Heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | USP2 4269/4885SMN1; SMN2 1111/4885ACACB 448/4885 |
| US-20260125387-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | MLLT1, MEN1, MLLT3 | USP2 3233/4885SMN1; SMN2 247/4885ACACB 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.